Purchase Order 75D30122P15542

Award Date 9/19/22
Potential Completion Date 9/18/23
Potential Value $237K
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive contract award to Bioreliance Corporation, a foreign-owned, for-profit organization, by the Centers for Disease Control and Prevention (CDC) Pittsburgh office. The $672,262.42 firm-fixed-price contract is for BIORELIANCE EXPI293F services, which likely includes specialized microbiological and scientific testing capabilities to support pharmaceutical and biotechnology research, such as endotoxin testing, sterility testing, and Limulus Amebocyte Lysate (LAL) testing. The...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a Firm Fixed Price Purchase Order to Bioreliance Corporation's Life Sciences Services Division, doing business as Bioreliance Corp De, for $15,434.00 in endotoxin and sterility testing services. The contract, which has a completion date of June 12, 2024, is to provide isolator sterility testing, Limulus Amebocyte Lysate (LAL) testing for...
This federal contract was awarded to Bioreliance Corporation, a foreign-owned, for-profit organization, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $6,065,128.00, is a definitive contract with a cost-plus-fixed-fee pricing type. Bioreliance, through its Life Sciences Services Division, will provide a range of specialized testing services to support investigational new drug...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,561.00 firm fixed price purchase order contract to Bioreliance Corporation, a foreign-owned for-profit company, to provide endotoxin, sterility, and general safety testing services in support of investigational new drug applications. The contract includes isolator sterility testing using direct inoculation methods, LAL testing for...
The Department of Health and Human Services National Institutes of Health (NIH) National Cancer Institute awarded a $80,848.00 Delivery Order contract to Bioreliance Corporation, a foreign-owned for-profit organization, for sterility testing services. The contract is for endotoxin, sterility, and general safety testing to support investigational new drug applications. Bioreliance has a history of providing these types of testing services to the NIH National Institute of Allergy and Infectious...
Bioreliance Corporation, a foreign-owned for-profit organization, was awarded a $34,978 firm-fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) to provide endotoxin, sterility, and general safety testing services in support of investigational new drug (IND) applications for NIAID's Pfs230D1-CRM197 and Pfs230D1-EPA malaria vaccine products. The contract, which does not have a set-aside designation, runs through August 31, 2024. Bioreliance has...
This is a Firm Fixed Price Delivery Order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Bioreliance Corporation, a foreign-owned for-profit organization. The contract, valued at $87,849.55, is for sterility testing services (STERILITY (510120GMP.BSV)) with a completion date of November 20, 2014. Bioreliance, through its Life Sciences Services Division, is a specialized provider of microbiological examination,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $15,434.00 firm-fixed-price purchase order to Bioreliance Corporation, a foreign-owned for-profit organization, for endotoxin and sterility testing services. The contract has an ultimate completion date of September 8, 2025. Bioreliance, through its Life Sciences Services division, provides specialized microbiological examination, bioburden...
This contract award is for the delivery of sterility units, catalog number 510011.BSV, to the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute. The prime contractor is Bioreliance Corporation, a foreign-owned for-profit organization that provides endotoxin, sterility, and general safety testing services through its Life Sciences Services division. The contract is a firm fixed-price delivery order with a potential value of $35,018.20...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute to Bioreliance Corporation, a foreign-owned for-profit organization that provides endotoxin, sterility, and general safety testing services through its Life Sciences Services division. The contract is for the delivery of Sterility Units, catalog number 510120GMP.BSV, with a firm fixed price of $35,018.20 and a completion date of June 30, 2013. No...

The Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh awarded a purchase order to Bioreliance Corporation's Life Sciences Services Division for $237,266.00 to provide laboratory services, including sterility testing. This firm fixed price contract has a completion date of September 18, 2023. Bioreliance, a foreign-owned for-profit organization, will provide sterility testing using direct inoculation methods, Limulus Amebocyte Lysate (LAL) testing for endotoxins, general safety testing, additional sterility testing, and shipping services in support of investigational new drug applications to the National Institute of Allergy and Infectious Diseases. Bioreliance has also provided microbiological examination and bioburden testing of drug products to the NIAID, as well as sterility testing services to the CDC in Pittsburgh. No set-aside designation was specified for this award.

Generated 3/23/24, 4:00 AM